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Background: Bone metastases (BM) are common in NSCLC patients. Despite some potential positive
effects of bone-targeted therapies, their use in NSCLC is infrequent, which may relate to the overall poor
prognosis of advanced lung cancer. We reviewed the literature to evaluate the incidence, consequences
and use of bone-targeting agents in lung cancer patients with BM in both the trial and non-trial clinical
setting.
Methods: Published prospective and retrospective papers investigating lung cancer and BM, in trial and
non-trial settings, were identiﬁed and are discussed in this review.
Results: BM are common in patients with advanced lung cancer and often present symptomatically
with pain and skeletal related events (SREs). Patients with high bone turnover marker levels, multiple
BM, and history of pathological fractures have shorter overall survival. In randomized studies bone-
targeted therapies reduced the risk of SREs and prolonged the time to ﬁrst SRE. The use of bone-
targeted agents may also be associated with a survival beneﬁt.
Conclusion: BM are a common problem in advanced lung cancer. While the beneﬁts of bone-targeted
therapies have been demonstrated, their use is limited in non-trial populations. If better predictive
markers of individual risk were available this might increase the appropriate use of bone-targeted agents.
& 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lung cancer is the most common cause of cancer-related
deaths worldwide [1]. With modern cancer therapies, the 5 year
survival rate for all lung cancer stages is around 16% [1], with a
median overall survival of 9–13 months for advanced non-
operable disease [2]. Bone is a common site of metastatic cancer
spread in NSCLC patients (20–40%), comparable in frequency
to liver (25–30%) and the contralateral lung (40–50%) [2–5].
The reported variability in sites of metastatic spread clearly
differs between studies and is associated with whether data
was obtained from imaging or autopsy series [6].
In patients who develop bone metastases, these are commonly
diagnosed at the time of their initial work up for their metastatic
disease (80%) [7], although others can develop skeletal metas-
tases at any time during the disease course. The consequences of
bone metastases include pain (80%) [3,6,8] and skeletal-related
events (SRE’s). SREs are deﬁned as: pathological fractures; spinal
cord or nerve root compression; the requirement for surgery or. This is an open access article un
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eatley-Price).radiotherapy to bone; or hypercalcemia of malignancy. SREs occur
in approximately half of lung cancer patients with bone metas-
tasis [3,9,10]. Not surprisingly, these events negatively impact
quality of life, performance status, and independent functioning.
In addition, patients who experience one SRE are then at sig-
niﬁcant risk for developing additional SRE’s and may possibly
have a shorter survival [3,9]. It is not surprising therefore that the
diagnosis of bone metastases and the occurrence of SREs fre-
quently require therapeutic intervention, with an associated
impact on increased health care costs [11,12].
The exact mechanism of bone breakdown is not fully under-
stood in lung cancer. However, it is likely similar to what has been
observed in bone metastases arising from other tumour types.
Bone breakdown, or osteolysis, results from a disruption of the
normal balance of bone resorption and formation controlled
by opposing functions of the osteoclast and the osteoblast.
As osteoclast activity is responsible for bone degradation, it has
become an important target for drug intervention leading to the
development of bisphosphonates and more recently the antibody
to the receptor activator of nuclear factor kappa-B ligand
(RANKL), denosumab. A number of trials have shown that treat-
ment with osteoclast inhibiting agents is associated with a
reduction in both the risk of, and time to development of SREs
[13–17].der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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patients with bone metastases arising from lung cancer (6–50%)
as compared with those from breast (80%) and prostate
cancers(23%–70%) [3,7,18–20]. The reasons for this discrepancy
are unknown, however may reﬂect the belief that patients with
bone metastases from advanced lung cancer already have such
a poor outcome that bone-targeted therapies are unlikely to
signiﬁcantly help as there is insufﬁcient time for signiﬁcant bone
re-modelling. To further evaluate whether this is true we decided
to review the literature in order to evaluate the frequency,
consequences, and outcome of patients with lung cancer and
bone metastases. We further examined literature describing the
impact of bone-targeted therapy in both clinical trial and non-
trial populations. This review could help determine whether or
not the use of these agents may be warranted.2. Methods
Searches were performed using Pubmed for articles published
between 1977 and 2012 on prospective and retrospective studies
related to lung cancer and bone metastasis. We initially identiﬁed
papers that included the keywords non-small cell lung cancer
and bone metastases. Using these initial search parameters, we
identiﬁed 376 published articles and abstracts. Subsequent the
further keywords: SRE, bisphosphonates, and denosumab were
searched with non-small cell lung cancer to identify other
relevant manuscripts. Further manuscripts were identiﬁed from
reference lists of the primary papers.
Studies that were not speciﬁc to lung cancer, pre-clinical
studies, other reviews and those not published in English were
excluded.
In this review we discuss both prospective randomized trial
data and ‘non-trial’ data, which is primarily comprised of retro-
spective series, retrospective analysis of prospective studies,
insurance claim data and prospective observational data.3. Results
In total, twenty nine articles matched the criteria for detailed
review. Most of the literature was ‘‘non-trial’’ data that consisted
of retrospective chart reviews, insurance claim data, retrospective
analyses of prospective trials and 1 prospective observational
study. ‘‘Trial’’ data included only two randomized, phase III (with
additional long-term data on one of them) trial, one randomised
phase II trial, two open label prospective and one single arm
prospective studies.Table 1
Consequences of the occurrence bone metastases and SREs on survival.
Study Overall survival without bone
metastases
Tsuya A et al., retrospective study 7.9 months
Sugiura H et al., retrospective study n/a
Sekine I et al., retrospective study n/a
Sun JM et al., retrospective study n/a
Spizzo G et al., retrospective study 15 months
Decroisette C et al., prospective, observation,
multicenter study
n/a
Rosen LS et al., prospective, randomized, phase III
study
n/a
Delea TE et al., retrospective study n/a3.1. Incidence and sites of bone metastases
The reported incidence of bone metastases in lung cancer was
found to be quite variable and dependent on diagnostic tools,
duration of follow up and the speciﬁc population studied. Earlier
studies (1970s–1990s) using mainly X-ray and bone scans,
reported an incidence of bone metastases in lung cancer patients
ranging between 8–20% [4,21–24]. More recent data including
that obtained from PET and CT scans has reported a higher
incidence of bone metastases ranging from 20–40% [3,7,25–28].
In these patients, 40–80% had bone metastases detected at the
time of initial staging for suspected advanced disease [1,3,4,7,9,29].
Bone only disease was relatively uncommon occurring in 1–7% of
lung cancer patients with advanced disease [4,30] comparing to
metastatic breast cancer were bone only involvement occurs in
about 17–37% of patients [31]. In addition, multiple bone meta-
static lesions were much more common (80%) than single sites of
bone metastases (20%) [9,26]. The spine was reported to be the
most common site of metastatic disease (40–50%), followed by ribs
(20–27%) and pelvis (17–22%) [3,7,26]. With respect to the histo-
logical type of lung cancer, most studies did not include patients
with small cell lung cancer (SCLC) and those that did rarely
discussed them separately from NSCLC. Hence it remains uncertain
whether the incidence of bone metastases differs between NSCLC
and SCLC.
3.2. Consequences of bone metastases
The consequences of bone metastases can be broadly divided
into reduced survival, SREs, and pain.
3.2.1. Overall survival
In breast cancer patients the presence of bone predominant
metastases appears is associated with longer survival compared
to the presence of visceral metastases [32]. In contrast, in lung
cancer patients the presence of bone predominant metastases is
not associated with longer survival [3] (Table 1). Indeed one small
retrospective study suggested a reduced survival for patients with
bone metastases compared to patients without bone metastases
(8.1 months vs. 15.1 months, p¼0.007) [27]. This however, could
reﬂect the fact that bone only metastatic disease is relatively
uncommon in advanced lung cancer patients, something quite
distinct from advanced breast cancer.
One retrospective study that evaluated predictors of survival
in lung cancer patients with bone metastases showed that
the presence of multiple bone metastases or the occurrence of
pathological fractures was associated with signiﬁcantly shorter
survival compared to patients with single metastases or no fractureOverall survival with bone
metastases
Overall survival with bone
metastases and SRE
Refs.
7.9 months 6.2 months [3]
7.2 months n/a [26]
15 months n/a [28]
12.7 months 12.3 months [7]
8 months n/a [27]
5.8 months 5.3 months [9]
6 months n/a [13]
2.5 months 3.8 months [12]
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presence of adenocarcinoma compared to the other types of lung
cancer, receiving chemotherapy, or treatment with EGFR tyrosine
kinase inhibitors (TKIs) were also associated with a more favour-
able prognosis (Table 2).
In order to assess impact of pathological fractures on survival
in different cancer types a retrospective analysis using data from
three large, phase III, placebo-controlled randomized studies
evaluating the efﬁcacy of zoledronic acid in multiple myeloma,Table 2
Predictor of survival in patients with bone metastasis of lung cancer [26].
Prognostic factors Survival,
months
p
Gender Female (n¼41) 13 0.02
Male (n¼77) 7.9
Performance status 0-1 (n¼67) 11.6 0.001
2–4 (n¼51) 7.1
Type of NSCLC Adenocarcinoma
(n¼83)
11.3 0.001
Other (n¼35) 5.8
Number of bone
metastases
Single (n¼19) 14 0.02
Multiple (n¼99) 8.9
Pathologic fracture No (n¼103) 10.2 0.04
Yes (n¼15) 6.4
Chemotherapy Yes (n¼67) 11.4 0.0009
No (n¼51) 7.5
EGFR TKI treatment Yes (n¼14) 17.8 0.0001
No (n¼104) 8.6
Table 3
Distribution of skeletal related events (SRE) between patients with bone metastases in
Type of study Pathological fractures (%) Spinal cord compression (%) Hypercalcemi
Trial
population
17 3 1%
21 4 3%
Non-trial
population
7.1 15.7 20.0%
16.4 6.7 9.2%
13.1 12.2 0.8%
0 0 4.8%
1.3 1.3 4.2%
10.3 14.9 n/a
13 1.7 n/a
35 6 7%
18.3 10.7 0%breast, prostate, lung and other tumour types was conducted [33].
The analysis demonstrated that patients with metastatic breast,
prostate cancer and multiple myeloma who had pathological
fracture were at increased risk for death. However, in metastatic
lung cancer patients there was no difference in survival between
patients with and without pathological fractures. This could be
explained by the short overall survival of advanced lung cancer
patients (183 days in placebo group and 203 in zoledronic acid
group, p¼0.623 in this analysis) entered into this study.
A retrospective analysis assessing the prognostic signiﬁcance
of baseline bone turnover markers in NSCLC patients with bone
metastases enroled into a prospective, phase III, randomized trial
comparing efﬁcacy of zoledronic acid to placebo was performed.
In this study, high versus normal baseline urinary NTX (N-telopeptide
of type I collagen) correlated with more than a twofold increased risk
of bone lesion progression and death in the placebo group (p¼0.039
and 0.001 respectively) [16]. This suggests a similar prognostic utility
of NTX in bone metastatic lung cancer as has been reported in other
tumour types [34].3.2.2. SREs3.2.2.1. Incidence of SREs in non-trial populations. SREs have been
used as a measure of the consequence of bone metastases and the
beneﬁts of bone-targeted therapies for over 20 years. In non-trial
populations, between 30–60% of patients with bone metastases
from lung cancer had at least one SRE and 30% of patients
experienced multiple SREs through the course of their disease
[3,7,9,10,27,28,35]. Both randomized and non-randomized datadifferent studies.
a Need to surgery (%) Need to radiotherapy (%) Refs.
4 26 ZA arm [13]
Patients with
BM¼523
5 32 Placebo arm
Patients with
BM¼250
0 34.3 [3]
Retrospective study
Patients with BM¼70
9.2 42 [9]
Prospective study
Patients with BM¼554
0.8 73.9 [7]
Retrospective study
Patients with BM¼273
0 19.5 [27]
Retrospective study
Patients with BM¼41
0.8 44 [28]
Retrospective study
Patients with BM¼243
12.6 49.4 [25]
Retrospective study
Patients with BM¼372
4.2 52 [26]
Retrospective study
Patients with BM¼118
14 68 [12]
Retrospective study
Patients with BM¼534
13.7 65.3 [35]
Retrospective study
Patients with BM¼196
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increases the risk of subsequent SREs [13,36].
The most commonly reported SREs in bone metastatic lung
cancer are radiotherapy (50–70%), pathologic fractures (7–35%),
hypercalcemia (1–20%), spinal cord compression (1–15%) and
surgery for bone metastases ( 0–9%) [3,7,26,28,35] (Table 3).
The median time to ﬁrst SRE was 8.9 months (95% CI, 6.1–11.7
months) in one retrospective study [7] (n¼273 patients), while
another reported that 31% of patients experienced their ﬁrst SRE
at time of initial diagnosis of bone metastases. (n¼70) [3]. Sekine
et al. reported that the ﬁrst SRE occurred within 6 months of
starting chemotherapy in 40.7% of cases (n¼243 patients with
bone metastases) [28]. An additional retrospective analysis of
2539 patients found the median time to ﬁrst SRE was as short as
40 days [37].
In breast and prostate cancer metastatic to bone, the literature
would suggest that patients with bone metastases who have an
SRE have a worse median survival than those patients with bone
metastases who do not have an SRE [33,38,39]. In contrast, the
lung cancer literature suggests that the occurrence of an SRE in
patients with bone metastases is not associated with a reduced
survival [9,10,12] (Table 1). However, it is unclear whether this is
simply a result of the generally reduced time of overall survival in
lung cancer versus breast or prostate cancer or is a speciﬁc
difference of the behaviour of the various tumour types in
the bone.
3.2.2.2. Incidence of SREs in clinical trial populations. Relatively few
clinical trials have reported randomized data assessing the effect
of bone-targeted therapies in lung cancer patients [13,17].
Of these, only one randomized study contained a placebo arm
[13]. In this trial comparing the efﬁcacy of zoledronic acid and
placebo in metastatic bone disease from solid tumours,
approximately half the enroled patients had metastatic lung
cancer. During the study which included 9 and 21 month follow
up data, the incidence of SREs was 44% and 46% respectively in
the placebo group (for all types of solid tumors, 50% of which
were lung cancer patients). Similar to the non-randomized
population, radiotherapy was the most common SRE (32%)
followed by pathological fractures (21%). However, spinal cord
compression and hypercalcemia of malignancy were lower in
these cohorts than in the non-trial populations. The average time
to ﬁrst on study SRE was 5 months [14] as compared to 1.5 to
8.9 months reported in non-trial settings [7,37].3.2.2.3. Predictors of individual patient SRE risk. In a retrospective
study looking at predictors of SRE risk in lung cancer patients with
bone metastases, it was found that patients with a history of smo-
king (5.2 months vs. 11.6 months, P¼0.004), non-adenocarcinoma
histology (3.1 months vs. 11.5 months, Po0.001), and no EGFR TKI
treatment (3.3 months vs. 11.8 months, Po0.001) had signiﬁcantly
shorter median time to ﬁrst SRE. These patients were at least twice as
likely to have SRE on univariate analysis, however on multivariate
analysis only ever smokers had statistically signiﬁcant increased risk
for SREs (odds ratio, 2.80; 95% CI, 1.32–6.00, p¼0.007) [7]. Recently
presented data supports a positive impact of EGFR activating
mutation (either exon 19 deletion or L858R in exon 21) on out-
come of patients with bone metastases secondary to lung cancer. The
incidence of SRE was signiﬁcantly lower (21% vs. 36%) and time to
ﬁrst SRE was longer (13 months vs. 6 months) in EGFR mutation
positive patients treated with an EGFR TKI, compared with EGFR
mutation negative patients mostly treated with platinum based
chemotherapy [40].
A further retrospective study evaluated risk factors for SREs
in metastatic lung cancer patients (with or without bonemetastases) receiving ﬁrst line palliative chemotherapy. This
demonstrated that male sex, poor performance status and the
presence of multiple bone metastases were associated with a
shorter time-to-the ﬁrst SRE and poor SRE-free survival [28].3.2.3. Pain
Pain occurs in 80% of lung cancer patients with bone
metastases [3,9]. Usually multiple therapeutic interventions
including localised therapies (radiotherapy and/or surgery)
systemic therapy (chemotherapy, bisphosphonates), and analge-
sics are required to manage pain associated with bone metas-
tases. There is limited data on the impact of EGFR inhibitors on
bone pain [41,42]. Surprisingly there is relatively little data
describing the degree of bone pain in the lung cancer literature,
and the majority of published data is restricted to describing the
incidence of bone pain and/or use of analgesics for pain. One
Japanese retrospective study reported an 80% incidence of pain,
70% use of non-steroidal anti-inﬂammatory drugs (NSAIDs) and
70% use of opioids in lung cancer patients with bone metastasis.
In a prospective observational French study, 89% of lung cancer
patients with bone metastases required analgesic treatment,
more than 70% of patients needed opioids, and 20% required
NSAIDs for pain control [3,9,25].
One of the most common treatments for palliation of bone
pain is radiation therapy, which can give pain relief in 65–100% of
cases. Two meta-analyses from a variety of tumor types including
lung cancer found the comparable efﬁcacy of different doses and
fractionations given for palliation of bone pain, however need for
re-treatment was signiﬁcantly higher in patients treated with a
single fraction regimen [43,44]. Therefore single fraction radio-
therapy is generally reserved for patients with poor performance
status and a short life expectancy [45].
3.3. Bone-targeted therapies in lung cancer
3.3.1. Clinical trial data
Data regarding the use of bisphosphonates in NSCLC patients
with bone metastases are surprisingly limited (Table 4). There is
only one prospective randomised trial that evaluated the efﬁcacy
of zoledronic acid (in two different doses of 4 mg and 8 mg, given
every 3 weeks, the 8 mg dose was subsequently reduced to 4 mg
due to concerns over renal safety at the higher dose) versus
placebo in lung cancer. This study enroled 773 patients with
metastatic bone disease secondary to solid tumors (excluding
breast and prostate cancer), and 378 patients had metastatic lung
cancer. The primary endpoint was the proportion of patients with
one or more SRE at 9 months and at 21 months. Zoledronic acid
was shown to delay time to the ﬁrst SRE (230 days vs. 163 days,
p¼0.023) and signiﬁcantly reduced the risk of developing SREs as
determined by multiple event analysis (HR¼0.73, p¼0.017) in all
tumour types. Reduction in number of SREs (hypercalcemia of
malignancy was excluded from analysis) did not reach statistical
difference for the comparison of 4 mg zoledronic acid versus
placebo (44% in placebo group vs. 38% in 4 mg zoledronic acid
group, p¼0.127), but the difference was signiﬁcant for 4/8 mg
zoledronic acid group compared to placebo ( 44% vs. 35%, p¼
0.023). When hypercalcemia of malignancy was added to the
analysis the difference in SRE was signiﬁcant in both groups (38%
vs. 47%, p¼0.039 in 4 mg zoledronic acid, 35% vs. 47% in 4/8 mg
zoledronic acid, p¼0.006) compared to placebo group. [13]. There
was no signiﬁcant difference in SRE outcomes between NSCLC and
other solid tumors on subgroup analysis. It is interesting to note
that the deﬁnition of SREs has also evolved over time. In all the
initial bisphophonate trials hypercalcaemia of malignancy was
classiﬁed as an SRE [46,47].
Table 4
Impact of bone-targeted agents on SREs.
Study Type of
tumour
Agents SRE
rate
Time to
1st SRE
Survival
Zoledronic acid vs. placebo in the treatment of skeletal metastases in patient with lung cancer
and other solid tumors: a phase III, double-blind, randomized trial [13].
NSCLC
50%
ZA 36% 236 days 189
Placebo 46% 155 days 183
Randomized, double-blind study of denosumab vs. zoledronic acid in the treatment of bone
metastases in patient with advanced cancer (excluding breast and prostate cancer) or
multiple myeloma [17].
NCSLC
40%
ZA n/a 489 days n/a
Denosumab n/a 618 days Signiﬁcant risk reduction of
death in NSCLC (HR 0.79)
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nancy was high enough to perform distinct clinical trials of
bisphosphonates in this patient population [48] Over time as the
incidence of hypercalcaemia has fallen with much wider use of
bone-targeted agents early in disease presentation as has increased
our knowledge around its aetiology and the pivotal role of PTHrP.
Hypercalcaemia in lung cancer is also seen as a result of ectopic
secretion of PTHrp in the absence of bone metastases [49].
Therefore in more recent trials some have classiﬁed hypercal-
caemia as an SRE for analysis [50] while others have not or make a
separate assessment [17,51,52].
Long term treatment and follow up of prospective randomized
comparison zoledronic acid to placebo conﬁrmed the efﬁcacy of
zoledronic acid in prolonging time to ﬁrst on-study SRE (236 days
vs. 155 days, p¼0.009) and reduction of annual incidence of SRE
(2.71 in placebo vs. 1.74 in zoledronic acid group, p¼0.012) [14]
in all types of cancer enroled in the trial. The retrospective
analysis of this prospective study has shown that zoledronic acid
reduced the risk of subsequent SREs by 31% in patients with
previous events [15], as well as could reduce relative risk of death
by 35% in patients with high baseline NTX levels at study
entry [16]. However, no overall survival beneﬁt was shown for
the study population as a whole [14]. No prospective randomized
phase 3 studies with any other bisphosphonate in comparison to
placebo have been performed in lung cancer patients.
Several small trials have investigated the use of bisphospho-
nates in metastatic lung cancer; however their measured out-
comes were mainly in terms of their impact on bone pain relief
and their ability to decrease pain or analgesic use [53–56]. One
open-label non-randomized study investigated 144 good perfor-
mance status patients with lung cancer metastatic to bone, where
87 patients had pain so received zoledronic acid along with
chemotherapy, whereas the 57 asymptomatic patients received
only chemotherapy. Investigators found improved tumour
response, prolonged time to progression (po0.001) and pro-
longed median survival (po0.001) in patients treated with
zoledronic acid [57]. Conclusions from the statistical analysis of
this paper should be interpreted with caution as it was a non-
randomised study with clearly unbalanced arms. In contrast, data
from a randomised, exploratory phase II study in 150 patients
with inoperable stage III and/or stage IV NSCLC failed to show any
difference in disease progression, time to progression and disease
progression to bone when zoledronic acid was added to che-
motherapy versus chemotherapy alone [58].
Recently published systematic review and meta-analysis
investigating a role of bisphosphonates in patients with lung
cancer and bone metastases found that patients treated with
zoledronic acid in addition to chemotherapy had signiﬁcantly
fewer SREs (RR 0.81, 95% CI 0.67–0.97). Pain control was better in
patients who received bisphosphonates in addition to chemother-
apy or radiotherapy (RR 1.18, CI 1.0–1.4). There was a trend to
increased overall survival but the difference did not reach
statistical signiﬁcance (mean 72 days, 95% CI 8.9–152.9) [59].Recently, the RANKL inhibitor denosumab has been compared
to zoledronic acid in a study that included 1776 patients with
bone metastases from solid tumors and multiple myeloma, 40% of
whom had metastatic lung cancer. In the whole study population
denosumab was non-inferior to zoledronic acid in delaying time
to ﬁrst on-study SRE: 20 months for denosumab vs. 16 months for
zoledronic acid (HR, 0.84; 95% CI, 0.71–0.98; p¼0.0007). There
was no difference in overall survival between the treatment
groups when all tumour types were considered. Of note,
a signiﬁcant reduction of relative risk of death was found during
a subset analysis of lung cancer patients; however, the authors
interpreted this ﬁnding with caution, suggesting it may be associated
with the heterogeneity of their study population [17]. Recently
presented data from a post-hoc analysis of this randomised phase
III trial has shown enhanced overall survival beneﬁt in both
adenocarcinoma (9.6 months for denosumab vs. 8.2 months for
zoledronic acid, HR¼0.80, 95% CI: 0.62–1.02; p¼0.0751) and squa-
mous cell carcinoma ( 8.6 months vs. 6.4 months, HR¼0.68, 95% CI:
0.47–0.97; p¼0.0350) in metastatic lung patients treated with
denosumab compared to those treated with zoledronic acid [60].3.3.2. Non-clinical trial data
Despite the reduction in SREs observed in clinical trials the
uptake for use of these agents in the lung cancer population has
been signiﬁcantly lower than that seen in other populations such
as breast and prostate cancers [3,7,9,18]. In the non-trial lung
cancer setting bisphosphonates were used in only 6%–20% [3] of
lung cancer patients with bone metastases and 10% of patients
received bisphosphonates after the ﬁrst occurrence of an SRE to
prevent additional events [7,9]. In a more recent prospective
observational French study, it was reported that only 50% of
lung cancer patients were treated with bisphosphonates at any
point during the course of their bone disease [9].
In another large retrospective study of 2539 lung cancer
patients with bone metastases (data was derived from a claims
database of 80 health plans across the US, from 2002–2006), 365/
2539 (14%) lung cancer patients were treated with zoledronic
acid. The treated patients tended to be younger and had lower
co-morbidity. In these patients the risk of SREs was reduced by 30–
40% (odds ratio [OR] 0.727; 95% CI, 0.594–0.890) and the time from
diagnosis of bone metastases to the ﬁrst bone complication was
increased by 85% (log regression model, 95% CI, 60.6–114.2%) [37].
An additional retrospective claims-based analysis of 9874 lung
cancer patients with bone metastases found that only 1090
patients (11%) were treated with zoledronic acid. In this treated
population the relative risk of pathological fractures was reduced
by 40% compared to the untreated population (p-0.005), although
the authors do not state the actual percentages of patients with
fracture in this analysis [61].
With respect to the impact of bisphosphonates on survival, a
small retrospective analysis assessing the efﬁcacy of pamidronate in
lung cancer patients with bone metastases (n¼41) demonstrated an
M. Kuchuk et al. / Journal of Bone Oncology 2 (2013) 22–29 27improvement in overall survival in pamidronate treated (n¼30)
versus not pamidronate treated patients (n¼11) (15 months vs.
2 months respectively, po0.001), however this should be inter-
preted with caution because of the extremely low numbers in this
study [27].
Comparing the data between trial and non-trial lung cancer
populations, the results for incidence and consequences of bone
metastases are comparable. They were also similar in terms of age
and extent of disease, however, it is clear that the performance
status of patients in clinical trial populations was higher than that
seen in the non-trial setting [7,9,13,17,26].4. Discussion
Retrospective, prospective, observational and clinical trial
datasets have all shown that bone metastases in lung cancer
patients are common and have important consequences for
patients. Moreover, their disease is complicated by a high inci-
dence of bone pain, SREs, impaired quality of life and a relatively
short overall survival.
Due to the unfavourable prognosis and short overall survival in
metastatic lung cancer patients, relatively little is known about
the impact of bone targeted therapy in these patients. Most
randomized trials which have evaluated these agents in lung
cancer patients with bone metastasis, were not designed to
speciﬁcally address the efﬁcacy in lung cancer patients only,
and included patients with different types of solid tumours.
However, despite the results of some clinical trials suggesting
that lung cancer patients with bone metastases could beneﬁt
from use of bone-targeted agents, it is evident that they are not
frequently used in the non-trial setting, and when they are, their
use appears to be restricted to younger patients or those with
better baseline performance status.
There is clearly much more to learn regarding the use of bone-
targeted agents in these patients. Although the data from clinical
trial cohorts compared to the general lung cancer population are
similar (particularly the incidence of SREs and survival) there are
a few notable differences between the datasets, such as the
performance status being slightly worse in the non-trial versus
trial populations [62].
There is also increasing evidence regarding the role of EGFR
TKIs, such as geﬁtinib and erlotinib, in the treatment of bone
metastases. In a Japanese series of 127 NSCLC patients with bone
metastases, of whom 50% had activating EGFR mutations, the
time to SRE was signiﬁcantly longer in mutation positive patients
treated with EGFR TKI than mutation negative patients (13 vs.
6 months, po0.05) [40]. It would be interesting to investigate the
impact on bone metastases in the numerous clinical trials that
have randomized patients to chemotherapy versus erlotinib or
geﬁtinib in EGFR mutation positive patients [63–66].
Finally, bone metastases and SREs contribute to the high
economic burden of the treatment of patients with metastatic
lung cancer [12]. The overall prognosis of metastatic lung cancer
patients is poor, however, given the high incidence of sympto-
matic SREs, pain emerging in the ﬁrst few months from diagnosis,
and the costs associated with treatment of their SREs, it seems
that these patients may signiﬁcantly beneﬁt from more routine
use of bone-targeted agents. We do however need better pre-
dictive markers for the development of bone metastasis and SRE’s
in lung cancer patients to guide clinicians in the more appropriate
use of bone targeted therapy for these patients. Some retro-
spective analyses suggest that high NTX levels, male sex, multiple
bone metastases, and poor performance status may be predictors
of SRE’s, however these should be further validated in additional
prospective cohorts.In summary, it is evident that bone metastases are a signiﬁcant
cause of increased morbidity and reduced quality of life in lung
cancer patients, thus new strategies are needed to enhance the
use of bone-targeted agents in this population. This will be of
increasing importance as the median survival of these patients
increases as a result of other therapeutic advances.Authors’ disclosure
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